---
---

# 42 U.S.C., USLM ref /us/usc/t42/s300aa–2

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../..//us/usc/t42/ch6A/schXIX/pt1/m__us_usc_t42_s300aa–1.md) | [Next](./../../../../../..//us/usc/t42/ch6A/schXIX/pt1/m__us_usc_t42_s300aa–3.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300aa%E2%80%932)

## § 300aa–2. Program responsibilities

    (a)

     The Director of the Program shall have the following responsibilities:

        (1) __Vaccine research__ 

            The Director of the Program shall, through the plan issued under [section 300aa–3 of this title][/us/usc/t42/s300aa–3], coordinate and provide direction for research carried out in or through the National Institutes of Health, the Centers for Disease Control and Prevention, the Office of Biologics Research and Review of the Food and Drug Administration, the Department of Defense, and the Agency for International Development on means to induce human immunity against naturally occurring infectious diseases and to prevent adverse reactions to vaccines.

        (2) __Vaccine development__ 

            The Director of the Program shall, through the plan issued under [section 300aa–3 of this title][/us/usc/t42/s300aa–3], coordinate and provide direction for activities carried out in or through the National Institutes of Health, the Office of Biologics Research and Review of the Food and Drug Administration, the Department of Defense, and the Agency for International Development to develop the techniques needed to produce safe and effective vaccines.

        (3) __Safety and efficacy testing of vaccines__ 

            The Director of the Program shall, through the plan issued under [section 300aa–3 of this title][/us/usc/t42/s300aa–3], coordinate and provide direction for safety and efficacy testing of vaccines carried out in or through the National Institutes of Health, the Centers for Disease Control and Prevention, the Office of Biologics Research and Review of the Food and Drug Administration, the Department of Defense, and the Agency for International Development.

        (4) __Licensing of vaccine manufacturers and vaccines__ 

            The Director of the Program shall, through the plan issued under [section 300aa–3 of this title][/us/usc/t42/s300aa–3], coordinate and provide direction for the allocation of resources in the implementation of the licensing program under [section 263a of this title][/us/usc/t42/s263a].

        (5) __Production and procurement of vaccines__ 

            The Director of the Program shall, through the plan issued under [section 300aa–3 of this title][/us/usc/t42/s300aa–3], ensure that the governmental and non-governmental production and procurement of safe and effective vaccines by the Public Health Service, the Department of Defense, and the Agency for International Development meet the needs of the United States population and fulfill commitments of the United States to prevent human infectious diseases in other countries.

        (6) __Distribution and use of vaccines__ 

            The Director of the Program shall, through the plan issued under [section 300aa–3 of this title][/us/usc/t42/s300aa–3], coordinate and provide direction to the Centers for Disease Control and Prevention and assistance to States, localities, and health practitioners in the distribution and use of vaccines, including efforts to encourage public acceptance of immunizations and to make health practitioners and the public aware of potential adverse reactions and contraindications to vaccines.

        (7) __Evaluating the need for and the effectiveness and adverse effects of vaccines and immunization activities__ 

            The Director of the Program shall, through the plan issued under [section 300aa–3 of this title][/us/usc/t42/s300aa–3], coordinate and provide direction to the National Institutes of Health, the Centers for Disease Control and Prevention, the Office of Biologics Research and Review of the Food and Drug Administration, the National Center for Health Statistics, the National Center for Health Services Research and Health Care Technology Assessment, and the Centers for Medicare & Medicaid Services in monitoring the need for and the effectiveness and adverse effects of vaccines and immunization activities.

        (8) __Coordinating governmental and non-governmental activities__ 

            The Director of the Program shall, through the plan issued under [section 300aa–3 of this title][/us/usc/t42/s300aa–3], provide for the exchange of information between Federal agencies involved in the implementation of the Program and non-governmental entities engaged in the development and production of vaccines and in vaccine research and encourage the investment of non-governmental resources complementary to the governmental activities under the Program.

        (9) __Funding of Federal agencies__ 

            The Director of the Program shall make available to Federal agencies involved in the implementation of the plan issued under [section 300aa–3 of this title][/us/usc/t42/s300aa–3] funds appropriated under [section 300aa–6 of this title][/us/usc/t42/s300aa–6] to supplement the funds otherwise available to such agencies for activities under the plan.

    (b) In carrying out subsection (a) of this section and in preparing the plan under [section 300aa–3 of this title][/us/usc/t42/s300aa–3], the Director shall consult with all Federal agencies involved in research on and development, testing, licensing, production, procurement, distribution, and use of vaccines.

([July 1, 1944, ch. 373][/us/act/1944-07-01/ch373], title XXI, § 2102, as added [Pub. L. 99–660, title III, § 311(a)][/us/pl/99/660/s311/a], Nov. 14, 1986, [100 Stat. 3756][/us/stat/100/3756]; amended [Pub. L. 102–531, title III, § 312(d)(13)][/us/pl/102/531/s312/d/13], Oct. 27, 1992, [106 Stat. 3505][/us/stat/106/3505]; [Pub. L. 108–173, title IX, § 900(e)(2)(F)][/us/pl/108/173/s900/e/2/F], Dec. 8, 2003, [117 Stat. 2372][/us/stat/117/2372].)

 __Prior Provisions__ 

    A prior section 300aa–2, act July 1, 1944, § 2103, was successively renumbered by subsequent acts and transferred, see [section 238b of this title][/us/usc/t42/s238b].

    A prior section 2102 of act July 1, 1944, was successively renumbered by subsequent acts and transferred, see [section 238a of this title][/us/usc/t42/s238a].

 __Amendments__ 

    2003—Subsec. (a)(7). [Pub. L. 108–173][/us/pl/108/173] substituted “Centers for Medicare & Medicaid Services” for “Health Care Financing Administration”.

    1992—Subsec. (a)(1), (3), (6), (7). [Pub. L. 102–531][/us/pl/102/531] substituted “Centers for Disease Control and Prevention” for “Centers for Disease Control”.

 __Grants for Research on Vaccine Against Valley Fever__ 

[Pub. L. 109–432, div. B, title IV, § 402][/us/pl/109/432/s402], Dec. 20, 2006, [120 Stat. 2994][/us/stat/120/2994], provided that:

>     “(a) __In General.—__ 

>     In supporting research on the development of vaccines against human diseases, the Secretary of Health and Human Services shall make grants for the purpose of conducting research toward the development of a vaccine against coccidioidomycosis (commonly known as Valley Fever).

>     “(b) __Sunset.—__ 

>     No grant may be made under subsection (a) on or after October 1, 2012. The preceding sentence does not have any legal effect on payments under grants for which amounts appropriated under subsection (c) were obligated prior to such date.

>     “(c) __Authorization of Appropriations.—__ 

>     For the purpose of making grants under subsection (a), there are authorized to be appropriated $40,000,000 for the period of fiscal years 2007 through 2012.”

 __Demonstration Projects for Outreach Programs__ 

[Pub. L. 101–502, § 2(b)][/us/pl/101/502/s2/b], Nov. 3, 1990, [104 Stat. 1285][/us/stat/104/1285], provided that:

>     “(1) __In general.—__ 

>     The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control, may make grants to public and nonprofit private entities for the purpose of carrying out demonstration projects—

>         “(A) to provide, without charge, immunizations against vaccine-preventable diseases to children not more than 2 years of age who reside in communities whose population includes a significant number of low-income individuals; and

>         “(B) to provide outreach services to identify such children and to inform the parents (or other guardians) of the children of the availability from the entities of the immunizations specified in subparagraph (A).

>     “(2) __Authorization of appropriations.—__ 

>     For the purpose of carrying out paragraph (1), there are authorized to be appropriated such sums as may be necessary for each of the fiscal years 1991 through 1993.”

    \[Centers for Disease Control changed to Centers for Disease Control and Prevention by [Pub. L. 102–531, title III, § 312][/us/pl/102/531/s312], Oct. 27, 1992, [106 Stat. 3504][/us/stat/106/3504].\]

 __Supply of Vaccines__ 

[Pub. L. 101–502, § 3][/us/pl/101/502/s3], Nov. 3, 1990, [104 Stat. 1285][/us/stat/104/1285], provided that:

>     “(a) __In General.—__ 

>     The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control, shall acquire and maintain a supply of vaccines sufficient to provide vaccinations throughout a 6-month period. Any proceeds received by the Secretary from the sale of vaccines from such supply shall be available to the Secretary for the purpose of purchasing vaccines for the supply. Such proceeds shall remain available for such purpose until expended.

>     “(b) __Authorization of Appropriations.—__ 

>     For the purpose of carrying out subsection (a), there are authorized to be appropriated $5,000,000 for fiscal year 1991, and such sums as may be necessary for each of the fiscal years 1992 through 1995.”

    \[Centers for Disease Control changed to Centers for Disease Control and Prevention by [Pub. L. 102–531, title III, § 312][/us/pl/102/531/s312], Oct. 27, 1992, [106 Stat. 3504][/us/stat/106/3504].\]

[Pub. L. 100–177, title I, § 110(b)][/us/pl/100/177/s110/b], Dec. 1, 1987, [101 Stat. 991][/us/stat/101/991], provided that:

>     “(1) __In general.—__ 

>     The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control, shall acquire and maintain a supply of vaccines sufficient to provide vaccinations throughout a 6-month period.

>     “(2) __Authorization of Appropriations.—__ 

>     There are authorized to be appropriated to carry out paragraph (1) $5,000,000 for fiscal year 1988, and such sums as may be necessary for each of the fiscal years 1989 and 1990.”

    \[Centers for Disease Control changed to Centers for Disease Control and Prevention by [Pub. L. 102–531, title III, § 312][/us/pl/102/531/s312], Oct. 27, 1992, [106 Stat. 3504][/us/stat/106/3504].\]

----------

[Previous](./../../../../../..//us/usc/t42/ch6A/schXIX/pt1/m__us_usc_t42_s300aa–1.md) | [Next](./../../../../../..//us/usc/t42/ch6A/schXIX/pt1/m__us_usc_t42_s300aa–3.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300aa%E2%80%932)

----------
----------

[/us/usc/t42/s300aa–3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300aa%E2%80%933
[/us/usc/t42/s300aa–3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300aa%E2%80%933
[/us/usc/t42/s300aa–3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300aa%E2%80%933
[/us/usc/t42/s300aa–3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300aa%E2%80%933
[/us/usc/t42/s263a]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs263a
[/us/usc/t42/s300aa–3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300aa%E2%80%933
[/us/usc/t42/s300aa–3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300aa%E2%80%933
[/us/usc/t42/s300aa–3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300aa%E2%80%933
[/us/usc/t42/s300aa–3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300aa%E2%80%933
[/us/usc/t42/s300aa–3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300aa%E2%80%933
[/us/usc/t42/s300aa–6]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300aa%E2%80%936
[/us/usc/t42/s300aa–3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300aa%E2%80%933
[/us/act/1944-07-01/ch373]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1944-07-01%2Fch373
[/us/pl/99/660/s311/a]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F99%2F660%2Fs311%2Fa
[/us/stat/100/3756]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F100%2F3756
[/us/pl/102/531/s312/d/13]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F102%2F531%2Fs312%2Fd%2F13
[/us/stat/106/3505]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F106%2F3505
[/us/pl/108/173/s900/e/2/F]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F108%2F173%2Fs900%2Fe%2F2%2FF
[/us/stat/117/2372]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F117%2F2372
[/us/usc/t42/s238b]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs238b
[/us/usc/t42/s238a]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs238a
[/us/pl/108/173]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F108%2F173
[/us/pl/102/531]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F102%2F531
[/us/pl/109/432/s402]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F109%2F432%2Fs402
[/us/stat/120/2994]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F120%2F2994
[/us/pl/101/502/s2/b]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F101%2F502%2Fs2%2Fb
[/us/stat/104/1285]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F104%2F1285
[/us/pl/102/531/s312]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F102%2F531%2Fs312
[/us/stat/106/3504]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F106%2F3504
[/us/pl/101/502/s3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F101%2F502%2Fs3
[/us/stat/104/1285]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F104%2F1285
[/us/pl/102/531/s312]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F102%2F531%2Fs312
[/us/stat/106/3504]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F106%2F3504
[/us/pl/100/177/s110/b]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F100%2F177%2Fs110%2Fb
[/us/stat/101/991]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F101%2F991
[/us/pl/102/531/s312]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F102%2F531%2Fs312
[/us/stat/106/3504]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F106%2F3504


